Clearance and Compliance: The FDA Blueprint for AI Medical Devices

The FDA has released a highly detailed draft guidance outlining exactly what manufacturers must include in marketing submissions for AI-enabled medical devices. We unpack the agency's strict expectations for data management, clinical validation, cybersecurity, and postmarket monitoring. Listeners will learn how to navigate total product lifecycle requirements and align their AI pipelines with federal standards.

Key points

• The FDA emphasizes a total product life cycle approach, requiring rigorous documentation from initial design through postmarket performance monitoring.
• Developers must actively manage AI bias by ensuring diverse training and testing data, analyzing subgroups like sex, age, race, and ethnicity, and clearly defining reference standards.
• Clinical validation must evaluate not just the standalone model, but the human-device team, using prespecified statistical plans and 95% confidence intervals.
• Cybersecurity for AI devices introduces novel threats like data poisoning and model evasion, requiring specific defenses like adversarial training and secure multi-party computation.
• Companies should consider Predetermined Change Control Plans to manage postmarket data drift and performance changes without always needing a new regulatory submission.

Source: Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations - U.S. Food and Drug Administration, 2025

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/clearance-and-compliance-the-fda-blueprint-for-ai-medical-devices-27f3ea